Kyntra Bio
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Kyntra Bio sits in the top decile of US sponsors by registered trial count (#538 of 15,742 sponsors by registered trial count).
Kyntra Bio: 30 sponsored US clinical trials, 1 recruiting.
Kyntra Bio sponsors 30 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 20 completed. 11 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastatic Castration-Resistant Prostate Cancer, with 1 trials.
Top-decile sponsor footprint
Kyntra Bio ranks in the top decile of sponsors by registered trial count (#538 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
20 of 29 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (69.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
30 total, page 1 of 1
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06842498
Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD
NCT04632940
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT04419558
Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
NCT04371666
Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants
NCT04484857
Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease
NCT04432298
Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants
NCT04410198
Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia
NCT04076943
Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT03955146
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
NCT03941093
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden
NCT03263091
Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
NCT02606136
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
NCT02273726
A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer
NCT02210559
Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants
NCT02052310
Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT01890265
A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis
NCT01750190
Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease
NCT01630889
Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment
NCT01414075
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
NCT01262001
Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia
NCT01244763
Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis
NCT01147666
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
NCT00913393
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
NCT01181245
Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)
NCT00782561
Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy
NCT00754143
Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis
NCT00761657
A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin
NCT00456053
Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus
NCT00102297
Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis
NCT00074698
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 13 |
| Phase 3 | 11 |
Therapeutic Areas
What is open in the Kyntra Bio pipeline
1 recruiting of 30 indexed (3% open); 20 completed (67%).
Phase mix: 11 late (III/IV) vs 19 early (I/II) (early-phase heavy).
Top condition: Metastatic Castration-Resistant Prostate Cancer (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Kyntra Bio: open-pipeline peers nationwide
Peers matched on 30 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Kyntra Bio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 30 trials (± recruiting share)
- Biotronik · 30 trials · 3% recruiting
- Charles Drew University of Medicine and Science · 30 trials · 3% recruiting
- Chiesi Farmaceutici S.p.A. · 30 trials · 13% recruiting
- Debiopharm International · 30 trials · 17% recruiting
Sponsors near 3% open enrollment (± trial volume)
- New York State Psychiatric Institute · 3% recruiting · 364 trials
- Wills Eye · 3% recruiting · 59 trials
- SCRI Development Innovations · 3% recruiting · 146 trials
- Halozyme Therapeutics · 3% recruiting · 31 trials
Related
What to do with this Kyntra Bio page
30 registered trials is a research-attention snapshot, not an endorsement of Kyntra Bio or any single study.
- 1 of Kyntra Bio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Metastatic Castration-Resistant Prostate Cancer is the condition Kyntra Bio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastatic Castration-Resistant Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Kyntra Bio pipeline card: 30 registered trials from official public datasets.Report a data error.